Publication - Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism

VHFC researchers at Tulane University have published findings in the Journal of Virology on an antiviral peptide with potential implications for Lassa fever (LF) treatment. Unlike ribavirin, the only drug currently used to treat LF, the peptide is not acutely toxic, and its activity is highly specific against arenaviruses. The peptide acts by a novel mechanism, causing premature conformational changes in viral surface proteins before the virus can bind to cells, effectively inactivating the pathogen.

Read the full article.

PSD to Drupal theme